Merck (MRK) news
Recent news
Merck & Co Inc: RBC cuts target price to $145 from $150
RBC Capital has adjusted its price target for Merck & Co Inc (MRK), lowering it to $145 from a previous target of $150. The revised forecast reflects updated expectations regarding the company’s performance and market conditions. While the change is relatively modest, it signals a cautious outlook…
AInvest Wire · 18h agoMerck & Co - Remigromig demonstrates non-inferior visual acuity versus ranibizumab at one year in DME
Merck & Co. has reported topline results from the pivotal phase 2b/3 BRUNELLO trial evaluating its investigational tetravalent, tri-specific antibody Remigromig (MK-3000) in patients with diabetic macular edema (DME). At 52 weeks, both tested doses of Remigromig (0.5 mg and 0.8 mg) demonstrated…
AInvest Wire · 2d agoVaxcyte closes $1.15B offerings of stock, warrants, notes
Vaxcyte, Inc. (Nasdaq: PCVX) has completed a $1.15 billion capital-raising initiative, comprising $500 million in common stock and pre-funded warrants and $500 million in convertible senior notes due 2032, with an additional $150 million in over-allotment options exercised by underwriters. The…
AInvest Wire · 3d agoBio-pharmaceutical stocks fell in intraday trading, with Eli Lilly down 4.73%, Amgen falling 2.93% and Merck sliding 2.33%.
Bio-pharmaceutical stocks experienced a decline in intraday trading on Monday, with several major players posting notable losses. Eli Lilly shares dropped 4.73%, while Amgen fell 2.93%. Merck also saw a decline, with its stock sliding 2.33% . The downward movement reflects broader market volatility…
AInvest Wire · 4d agoPerspective Thera gets designation for PSV359
Perspective Therapeutics has announced a clinical collaboration with Merck to evaluate its targeted alpha therapy, [212Pb]PSV359, in combination with Merck’s anti-PD-1 therapy Keytruda (pembrolizumab) for the treatment of FAP-α-positive solid tumors. The collaboration involves amending…
AInvest Wire · 4d agoLight Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.